Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $160 from $175 and keeps an Overweight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis Stock (ZTS) Climbs as $1.75B Convertible Plan Boosts Confidence in Growth Strategy
- Zoetis files to sell $1.75B in senior convertible notes due 2029
- BofA shakes up ratings in Biopharma Services with seven changes
- Zoetis downgraded to Neutral from Buy at BofA
- Zoetis Announces 6% Increase in Quarterly Dividend